The British Columbia COVID-19 Therapeutics Committee provides guidance on the most current research on the use of therapies in the management of COVID-19.
Antimicrobial and Immunomodulatory Therapy in Adult Pregnant Patients - updated December 21, 2021
Clinical Practice Guide for the Use of REGEN-COV in Inpatients with COVID-19 - new November 18, 2021
Clinical Practice Guide for the Use of Sotrovimab in Patients with COVID-19 -
updated January 10, 2022
The British Columbia COVID-19 Therapeutics Committee (CTC) meets regularly to discuss the most current research on the use of therapies in the management of COVID-19.
There is evidence to support the use of many therapies that have been proven to work in the treatment of COVID-19, highlighted below. Within British Columbia, the use of unproven COVID-19 drug therapies outside of clinical trials is NOT recommended.
These recommendations apply to hospitalized and non-hospitalized adult patients with confirmed or suspected COVID-19. Find recommendations for Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19.
i) Non hospitalized patients with no oxygen requirements
In adults with mildly ill COVID-19 aged 65 and over OR aged 50 and over with underlying health conditions and within 14 days of symptom onset, inhaled budesonide 800 μg twice daily for 14 days may be considered on a case by case basis in discussion with the patient by clearly highlighting the uncertainty in the benefit of treatment, and the risks and potential adverse effects. Informed consent should be obtained and treatment initiated as soon as possible. Underlying health conditions include weakened immune system due to illness or medication; heart disease and/or hypertension; chronic lung disease; diabetes; hepatic impairment; stroke or other neurological condition; obesity or BMI above 35.
ii) Hospitalized patients requiring oxygen or higher levels of respiratory support
Dexamethasone 6 mg IV/PO q24h for up to 10 days is strongly recommended (RECOVERY trial), unless higher doses are clinically indicated (e.g. asthma exacerbation, refractory septic shock, history of chronic steroid use, obstetric use for fetal lung maturation).
Hydrocortisone 50 mg IV q6h is recommended as an alternative (REMAP-CAP trial). If dexamethasone and hydrocortisone are not available, methylprednisolone 32 mg IV q24h or prednisone 40 mg PO daily are recommended.
Tocilizumab 400mg IV (single dose) OR
Sarilumab 400mg IV (single dose) is recommended (REMAP-CAP, RECOVERY) for patients requiring life support due to confirmed COVID-19. This includes high-flow oxygen support (e.g., Optiflow) if flow rate > 30 L/min and FiO2 > 0.4 OR invasive or non-invasive ventilation OR vasopressor or inotropic support. Tocilizumab or sarilumab must be administered within 24 hours of the initiation of life support measures. Patients admitted to hospital for more than 14 days with symptoms of COVID-19 should not receive tocilizumab or sarilumab for this indication. Tocilizumab or sarilumab should only be initiated when life support is required because of COVID-19 rather than other causes (such as bacterial infection, pulmonary embolism, etc).
If tocilizumab is not available due to ongoing global shortages, baricitinib is recommended as an alternative.
Baricitinib 4 mg po daily (for patients with GFR ≥ 60 mL/min) or 2 mg po daily (for patients with GFR 30-59 mL/min) or 2 mg po every 2nd day (for patients with GFR 15-29 mL/min) up to 14 days, or until discharge from hospital (whichever occurs first) is recommended (COV-BARRIER) for patients requiring life support due to confirmed COVID-19. This includes high-flow oxygen support (e.g., Optiflow) if flow rate > 30 L/min and FiO2 > 0.4 OR invasive or non-invasive ventilation OR vasopressor or inotropic support. Baricitinib should be administered within 24
hours of the initiation of life support measures. Baricitinib should only be initiated when life support is required because of COVID rather than other causes (such as bacterial infection, pulmonary embolism, etc). Baricitinib should not be administered to patients with neutrophils <1.0 giga/L, lymphocytes < 0.2 giga/L, ALT or AST > 5 x ULN, or eGFR < 15 mL/min (or receiving renal replacement therapy).
*There are very limited data on baricitinib in pregnancy. Risks and benefits of baricitinib should be discussed on a case by case basis with pregnant women with severe COVID-19.
Tocilizumab is not recommended for patients receiving low-flow oxygen support. The RECOVERY trial found a survival benefit of 4% (tocilizumab 29% vs. usual care 33% 28-day mortality) in patients who had CRP >75 mg/L AND low-flow oxygen, non-invasive respiratory support, or invasive mechanical ventilation. However, considering the scarcity of IL-6 blockers in Canada, drug therapy should be prioritized to the persons with both the highest need and the greatest likelihood of benefiting from the therapy. Combined with outstanding issues in the preliminary findings of the RECOVERY trial (e.g. 17% of patients randomized to tocilizumab not receiving the drug), the CTC recommends prioritizing tocilizumab use only for critically ill patients at this time, which is the population shown to benefit in both the REMAP and RECOVERY trials.
i) Hospitalized patients requiring low-flow oxygen
Therapeutic anticoagulation (LMWH preferred) may be beneficial and therefore considered in patients without high risk features* for serious bleeding and NOT requiring organ support. If used, anticoagulation for COVID-19 should start within 72 hours of admission and continue for 14 days or until hospital discharge. Patients who decompensate and require organ support while on therapeutic anticoagulation should continue on therapeutic anticoagulation. Therapeutic anticoagulation was superior to standard of care for composite 21-day organ support free survival in the ATTACC/ACTIV-4a/REMAP-CAP trials. Benefits appear to be driven by reducing progression to high-flow oxygen, non-invasive ventilation, or vasopressors. There was insufficient certainty on whether therapeutic anticoagulation improves mortality or intubation. Therapeutic anticoagulation reduces thrombotic events (1.4% vs 2.7%) but may increase major bleeding (1.9% vs 0.9%). *High risk features for bleeding include: age 75 or greater, eGFR less than 30 mL/min, any coagulopathy, platelet count less than 50, use of dual antiplatelet therapy, recent history of serious GI bleed or recent intracranial condition (stroke, neurosurgery, aneurysm, cancer), epidural or spinal catheter.
ii) Hospitalized patients requiring organ support (high-flow oxygen, noninvasive ventilation, mechanical ventilation and/or vasopressor/inotropic support)
Prophylactic-intensity dosing of low molecular weight heparin (LMWH) is recommended for VTE prophylaxis in patients who do not have suspected or confirmed VTE (or other indications for therapeutic anticoagulation). There is a high probability of harm when therapeutic anticoagulation is initiated in patients who have received organ support for greater than 48 hours (n=1074; NIH mpRCT). Patients receiving therapeutic anticoagulation for COVID-19 prior to organ support should REMAIN on therapeutic anticoagulation and continue for up to 14 days or until hospital discharge.
In outpatients aged 40 years or older with PCR-confirmed COVID-19 who have at least one risk factor† and no contraindications††, colchicine 0.6 mg PO BID x 3 days, then 0.6 mg daily x 27 days may be considered on a case-by-case basis in discussion with the patient by clearly highlighting the uncertainty in the benefit of treatment, and the risks and potential adverse effects. Informed consent should be obtained and treatment initiated as soon as possible.
Remdesivir has not demonstrated benefit in survival, progression to ventilation or length of hospital stay and remains uncertain with respect to shortening time to recovery by 5 days. The World Health Organization (WHO) has issued a conditional recommendation against the use of remdesivir in hospitalized COVID-19 patients. Further evaluation in approved clinical trials is strongly encouraged. If remdesivir is used outside of clinical trials, full disclosure of risks and benefits with consideration of patient values and preferences are necessary, as it is not considered standard of care. Furthermore, it should be restricted to hospitalized patients requiring supplemental oxygen but not requiring non-invasive or invasive mechanical ventilation.
Lopinavir/ritonavir is not recommended for treatment of COVID-19. Lopinavir/ritonavir is not recommended for prophylaxis of COVID-19 outside of approved randomized-controlled trials.
Chloroquine or hydroxychloroquine (with or without azithromycin) is not recommended for treatment or prophylaxis of COVID-19.
Oseltamivir is not recommended for treatment or prophylaxis of COVID-19.
Interferon IV/SC is not recommended for the treatment of COVID-19. Ribavirin/Interferon (Inhaled) is not recommended outside of approved clinical trials.
Based on the current scientific evidence and best-practice guidelines, the College of Physicians and Surgeons of BC, the College of Pharmacists of BC, the BC College of Nurses and Midwives and the CTC do not approve of the use of ivermectin for either treatment or prophylaxis for COVID-19 and registrants must not prescribe it for this purpose.Ivermectin should not be used outside of approved randomized-controlled trials.
Ascorbic acid and Vitamin D are not recommended for treatment or prophylaxis of COVID-19 outside of approved randomized-controlled trials.
Convalescent plasma# is not recommended for treatment or prophylaxis of COVID-19 outside of approved randomized-controlled trials.
Intravenous immunoglobulin G (IVIG) is not recommended for treatment or prophylaxis of COVID-19 outside of approved randomized-controlled trials.
Monoclonal antibodies (mAbs; Bamlanivimab/etesevimab, REGN-COV2, Sotrovimab, Regdanvimab) are NOT recommended. An RCT of REGN-COV2 in this population was halted due to signals of harm. Regdanvimab conditions for use state that it may be associated with worse outcomes in the critically ill. RECOVERY showed no benefit in the subgroup that required organ support. Various guidelines (IDSA, NIH, INESSS) recommend against mAbs in this setting.
Monoclonal antibodies (mAbs; Bamlanivimab/etesevimab, REGN-COV2, Sotrovimab, Regdanvimab) are not recommended. MAbs have shown inconsistent results in RCTs. TICO was stopped for futility as mortality was numerically higher in the Bamlanivimab arm. RECOVERY demonstrated a mortality benefit with REGN-COV2, but only in seronegative patients, with signals of harm in seropositive patients. Reliable rapid antibody tests to identify the target population are not readily available and all mAbs remain unapproved in Canada for in-patients with COVID-19.
Monoclonal antibodies (mAbs; Bamlanivimab/etesevimab, REGN-COV2, Sotrovimab, Regdanvimab) IV have shown to reduce hospitalization rates (although not mortality or length of stay) in UNVACCINATED outpatients at high-risk of complications due to comorbidities (age >40 with a comorbidity like obesity or hypertension). Due to high vaccination rates and barriers to operationalizing outpatient IV administration outside of clinical trials, the clinical application of these studies is limited. mAbs may be considered on a case-by-case basis in those inadequately immunized (unimmunized, partially immunized or inadequate immune response) with mild disease AND who are at high risk of developing severe COVID-19-related complications. The subcutaneous route has shown similar reductions in viral loads, but clinical data is lacking and would still present operational barriers such as multiple injections and required observation time.
Bamlanivimab/etesevimab IV has shown to reduce the development of symptomatic COVID-19 as prophylaxis in unvaccinated LTC residents, as has subcutaneous REGN-COV2 given to unvaccinated, seronegative, PCR-negative household contacts if given within 96 hours of exposure. Due to lack of reliable rapid tests to identify the target population within the prophylaxis window, lack of impact on hospitalization rates or mortality and low generalizability of these studies, mAb administration is not recommended for post-exposure prophylaxis.
Antibiotics should be initiated based on local institutional antibiograms and sensitivities if bacterial infection is suspected.
Acetaminophen is recommended preferentially for symptomatic management of COVID-19 but do not recommend against the use of NSAIDs such as ibuprofen.
Patients on ACE inhibitors and ARBs are recommended to continue these agents as indicated and not cease therapy solely on the basis of COVID-19.
SSRIs are not recommended for treatment or prophylaxis of COVID-19 outside of approved randomized-controlled trials.
Other investigational agents including arbidol, ASC09, azvudine, baloxavir marboxil/favipiravir, camostat mesylate, darunavir/cobicistat, camrelizumab, famotidine, niacin, thymosin, natural health products, and traditional Chinese medicines are not recommended for treatment or prophylaxis of COVID-19 due to lack of data, lack of availability, or both.
# Denotes that a clinical trial of named therapy is currently planned or underway in British Columbia.
Links to listing of registered trial in British Columbia and Canada:
*Recommendations are consistent with guidelines from the World Health Organization (WHO), the Surviving Sepsis Campaign (SSC) (a joint initiative of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM)), the Public Health Agency of Canada (PHAC), the Canadian Critical Care Society (CCCS), the Association of Medical Microbiology and Infectious Diseases Canada (AMMI), and The Australian and New Zealand Intensive Care Society (ANZICS).
†Age >70 years, obesity (BMI >30 kg/m2), diabetes, hypertension (systolic >150 mmHg), respiratory or coronary disease, heart failure, fever >38.4°C, and dyspnea.
††Contraindications – GFR <30 mL/min, inflammatory bowel disease, chronic diarrhea or malabsorption, neuromuscular disease, severe liver disease, chemotherapy, current colchicine treatment, hypersensitivity to colchicine, or concurrent medications that interact with colchicine (e.g. amiodarone, azoles, carvedilol, cyclosporine, estradiol, macrolides, propafenone, protease inhibitors, quinidine, quinine, verapamil).